Technical Analysis for EYES - Second Sight Medical Products, Inc.

Grade Last Price % Change Price Change
grade B 5.71 5.55% 0.30
EYES closed up 5.55 percent on Friday, February 21, 2020, on 22 percent of normal volume.

Trend Table & Recent Signals

ADX Long Term Intermediate Term Short Term
Strong Up Up Up
Historical EYES trend table...

Date Alert Name Type % Chg
20 DMA Support Bullish 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 0.00%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 0.00%
Outside Day Range Expansion 0.00%
Wide Bands Range Expansion 0.00%
1,2,3 Pullback Bullish Bullish Swing Setup 5.55%
Non-ADX 1,2,3,4 Bullish Bullish Swing Setup 5.55%
Narrow Range Bar Range Contraction 5.55%
NR7 Range Contraction 5.55%
Inside Day Range Contraction 5.55%

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:


Second Sight Medical Products, Inc. was founded in 1998 with a mission to restore vision to the blind. Today, Second Sight’s Argus II retinal prosthesis provides functional vision to patients blinded by outer retinal degenerations such as retinitis pigmentosa. The company’s innovative technology is the only retinal prosthesis approved by the United States FDA and the first device to receive a CE mark in Europe. The company’s transformative prosthetic device allows blind individuals to gain greater independence in their daily lives. Second Sight believes that its award winning technology will serve as a platform to treat nearly all forms of blindness and could be extended to other neurostimulation applications beyond vision restoration. The Argus II system is currently available in the US and Europe and the company is actively pursuing additional geographic markets. With next generation products under development, the company plans to continue developing, manufacturing and marketing its innovative visual prostethics around the world. Second Sight’s US Headquarters are in Sylmar, California. European Headquarters are in Lausanne, Switzerland.
Medicine Biotechnology Emerging Technologies Medical Devices FDA Vision Blindness Retinitis Pigmentosa Biomedical Engineering Neuroprosthetics Neurostimulation

Is EYES a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength


Indicator Value
52 Week High 6.4
52 Week Low 0.64
Average Volume 131,963
200-Day Moving Average 1.53
50-Day Moving Average 3.67
20-Day Moving Average 5.30
10-Day Moving Average 5.66
Average True Range 0.49
ADX 47.91
+DI 33.52
-DI 12.22
Chandelier Exit (Long, 3 ATRs ) 4.92
Chandelier Exit (Short, 3 ATRs ) 5.04
Upper Bollinger Band 6.24
Lower Bollinger Band 4.36
Percent B (%b) 0.72
BandWidth 35.43
MACD Line 0.50
MACD Signal Line 0.60
MACD Histogram -0.098
Fundamentals Value
Market Cap 324.28 Million
Num Shares 56.8 Million
EPS -0.71
Price-to-Earnings (P/E) Ratio -8.04
Price-to-Sales 12.04
Price-to-Book 3.29
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 6.49
Resistance 3 (R3) 6.42 6.08 6.36
Resistance 2 (R2) 6.08 5.88 6.12 6.32
Resistance 1 (R1) 5.90 5.76 5.99 5.97 6.27
Pivot Point 5.56 5.56 5.61 5.60 5.56
Support 1 (S1) 5.38 5.36 5.47 5.45 5.15
Support 2 (S2) 5.04 5.24 5.08 5.10
Support 3 (S3) 4.86 5.04 5.06
Support 4 (S4) 4.93